ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Sun Pharmaceutical Industries and Pfizer side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Sun Pharmaceutical IndustriesPfizer
studies on the registry3284,073
open to participants now11147
phase 3 studies under way999
reach primary completion within a year593
programswith a study of their own in two years1491+9 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseSun Pharmaceutical IndustriesPfizer
Phase 1

Sun Pharmaceutical Industries: 10 of its 14 programs at phase 1

  1. DL2phase 1
  2. DL3phase 1
  3. DL4phase 1
  4. DL5phase 1
  5. Dose level (DL)1phase 1

and 5 more — sign in to see them all

71%

Pfizer: 42 of its 91 programs at phase 1

  1. polfurmetinibphase 1
  2. claturafenibphase 1
  3. PF-07985631phase 1
  4. PF-08642534phase 1
  5. Anti-integrin Beta-6 Antibody-drug Conjugate PF-08046876phase 1

and 37 more — sign in to see them all

46%
Phase 2

Sun Pharmaceutical Industries: 1 of its 14 programs at phase 2

  1. utreglutidephase 2
7%

Pfizer: 10 of its 91 programs at phase 2

  1. PF-07328948phase 2
  2. tegtociclibphase 2
  3. PF-08653945phase 2
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 5 more — sign in to see them all

11%
Phase 3

Sun Pharmaceutical Industries: 2 of its 14 programs at phase 3

  1. Deuruxolitinibphase 3
  2. Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%phase 3
14%

Pfizer: 31 of its 91 programs at phase 3

  1. berobenatidephase 3
  2. tivunatamigphase 3
  3. tilrekimigphase 3
  4. ritlecitinibphase 3
  5. abrysvophase 3

and 26 more — sign in to see them all

34%
Approved, new studies

Sun Pharmaceutical Industries: 1 of its 14 programs at approved, new studies

  1. Phenobarbitalapproved, new study
7%

Pfizer: 8 of its 91 programs at approved, new studies

  1. rimegepantapproved, new study
  2. tucatinibapproved, new study
  3. elranatamabapproved, new study
  4. tisotumab vedotinapproved, new study
  5. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineapproved, new study

and 3 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Sun Pharmaceutical Industries4 readouts · 2 phase 3·

Sun Pharmaceutical Industries, Dec ’26: 1 program whose next study reaches primary completion

  1. Drugs, Investigationalphase 1 · Dec 0 · NCT07729579

Sun Pharmaceutical Industries, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%phase 3 · Jan 0 · NCT07144345
··

Sun Pharmaceutical Industries, Apr ’27: 1 program whose next study reaches primary completion

  1. utreglutidephase 2 · Apr 0 · NCT07282743

Sun Pharmaceutical Industries, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Deuruxolitinibphase 3 · May 0 · NCT03898479
·····
Pfizer37 readouts · 10 phase 3

Pfizer, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. rimegepantapproved, new study · Nov 29 · NCT06641466

Pfizer, Dec ’26: 8 programs whose next study reaches primary completion, 2 in phase 3

  1. ritlecitinibphase 3 · Dec 2 · NCT07029711
  2. vepdegestrantphase 3 · Dec 4 · NCT07231991
  3. VLA15phase 3 · Dec 4 · NCT07500506
  4. prifetrastatphase 3 · Dec 8 · NCT07721402
  5. disitamab vedotinphase 3 · Dec 11 · NCT04879329

and 3 more — sign in to see them all

Pfizer, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08653945phase 2 · Jan 13 · NCT07725809
  2. abrysvophase 3 · Jan 18 · NCT05035212
  3. berobenatidephase 3 · Jan 27 · NCT07508241

Pfizer, Feb ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. osivelotorphase 3 · Feb 8 · NCT06507904
  2. tilrekimigphase 3 · Feb 20 · NCT07792941
  3. PF-07328948phase 2 · Feb 23 · NCT07269301
  4. atirmociclibphase 3 · Feb 26 · NCT05262400
  5. mevrometostatphase 3 · Feb 28 · NCT06551324

Pfizer, Mar ’27: 3 programs whose next study reaches primary completion

  1. PG4phase 3 · Mar 4 · NCT06524414
  2. PF-08161842phase 1 · Mar 17 · NCT07897708
  3. PF-08103402phase 1 · Mar 30 · NCT07660731

Pfizer, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08642534phase 1 · Apr 21 · NCT07731139
  2. PG4 Multivalent Vaccinephase 3 · Apr 26 · NCT07794748

Pfizer, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abrocitinibphase 3 · May 2 · NCT06807268
  2. marstacimabphase 3 · May 5 · NCT06703606

Pfizer, Jun ’27: 3 programs whose next study reaches primary completion

  1. PF-07832837phase 1 · Jun 2 · NCT06564389
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3 · Jun 10 · NCT07023081
  3. sigvotatug vedotinphase 3 · Jun 16 · NCT04389632
·

Pfizer, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. elranatamabapproved, new study · Aug 4 · NCT05317416
  2. zavegepantphase 3 · Aug 12 · NCT06995729
  3. claturafenibphase 1 · Aug 31 · NCT05355701
  4. polfurmetinibphase 1 · Aug 31 · NCT05538130

Pfizer, Sep ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. PF-08065010phase 1 · Sep 1 · NCT07235163
  2. ibuzatrelvirphase 3 · Sep 28 · NCT07013474
  3. remdesivirphase 3 · Sep 28 · NCT07013474

Pfizer, Oct ’27: 3 programs whose next study reaches primary completion

  1. tivunatamigphase 3 · Oct 18 · NCT07227012
  2. PA-001phase 1 · Oct 21 · NCT07086677
  3. PG4 in Buffer 1 with low dose PA-002phase 1 · Oct 21 · NCT07086677
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Sun Pharmaceutical Industries

New programs 1

  • Phenobarbitalapproved, new study · first study · Oct 13 · Seizures

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Pfizer

New programs 6

Reached a new phase 0

None

Study stopped 3

  • PF-07868489phase 2 · terminated Nov 2 · none of its studies left running“The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” · NCT07073820
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. T…” · NCT05573555
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. Th…” · NCT06125522

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 6 in all. A program counts in each condition its studies name most.

ConditionSun Pharmaceutical IndustriesPfizer
Dermatitis, Atopicboth · compare here

Sun Pharmaceutical Industries in Dermatitis, Atopic: 2 programs

  1. Ivermectinphase 1
  2. tapinarofphase 1

Their studies: Sun Pharmaceutical Industries’ studies of Dermatitis, Atopic in search

Pfizer in Dermatitis, Atopic: 7 programs

  1. tilrekimigphase 3
  2. abrocitinibphase 3
  3. etrasimodphase 3
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Dermatitis, Atopic in search

COVID-19both · compare here

Sun Pharmaceutical Industries in COVID-19: 1 program

  1. Ivermectinphase 1

Their studies: Sun Pharmaceutical Industries’ studies of COVID-19 in search

Pfizer in COVID-19: 5 programs

  1. abrysvophase 3
  2. ibuzatrelvirphase 3
  3. zavegepantphase 3
  4. remdesivirphase 3
  5. PA-001phase 1

Their studies: Pfizer’s studies of COVID-19 in search

Renal Insufficiencyboth · compare here

Sun Pharmaceutical Industries in Renal Insufficiency: 1 program

  1. Deuruxolitinibphase 3

Their studies: Sun Pharmaceutical Industries’ studies of Renal Insufficiency in search

Pfizer in Renal Insufficiency: 4 programs

  1. prifetrastatphase 3
  2. abrocitinibphase 3
  3. osivelotorphase 3
  4. PF-07328948phase 2

Their studies: Pfizer’s studies of Renal Insufficiency in search

Alopecia Areataboth · compare here

Sun Pharmaceutical Industries in Alopecia Areata: 1 program

  1. Deuruxolitinibphase 3

Their studies: Sun Pharmaceutical Industries’ studies of Alopecia Areata in search

Pfizer in Alopecia Areata: 2 programs

  1. ritlecitinibphase 3
  2. etrasimodphase 3

Their studies: Pfizer’s studies of Alopecia Areata in search

Diabetes Mellitus, Type 2both · compare here

Sun Pharmaceutical Industries in Diabetes Mellitus, Type 2: 1 program

  1. utreglutidephase 2

Their studies: Sun Pharmaceutical Industries’ studies of Diabetes Mellitus, Type 2 in search

Pfizer in Diabetes Mellitus, Type 2: 2 programs

  1. berobenatidephase 3
  2. danuglipronphase 2

Their studies: Pfizer’s studies of Diabetes Mellitus, Type 2 in search

Psoriasisboth · compare here

Sun Pharmaceutical Industries in Psoriasis: 1 program

  1. tapinarofphase 1

Their studies: Sun Pharmaceutical Industries’ studies of Psoriasis in search

Pfizer in Psoriasis: 1 program

  1. abrocitinibphase 3

Their studies: Pfizer’s studies of Psoriasis in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Sun Pharmaceutical Industries 3 of 14 · Pfizer 67 of 91 programs (19 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Pfizer: 9).